Results 141 to 150 of about 136,268 (220)

Design Space Assessment of Virus Inactivation in Plasma‐Derived Matrices Establishes a Single Detergent Alternative to TX‐100‐Containing Mixes

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The detergent Triton X‐100 (TX‐100) is a typical component of solvent/detergent (S/D) mixes applied for virus inactivation steps of biomanufacturing processes, yet environmentally unfavorable properties have led to restrictions on its use. Deviron 13‐S9 has recently been described as an eco‐friendly TX‐100 alternative, with powerful virus ...
Johanna Kindermann, Cecilie Klausen, Michael Karbiener, Thomas R. Kreil   +3 more
wiley   +1 more source

Antibody display technologies from phages to cells: translational bottlenecks and AI-enabled opportunities. [PDF]

Front Bioeng Biotechnol
Sahu A, Das P, Das R, Bhattacharya I, Bhattacharya T, Mohan U, Sreedhar R, Arumugam S.   +7 more
europepmc   +1 more source

Marine silicon for biomedical sustainability

BMEMat, EarlyView.
Schematic illustrating marine silicon for biomedical engineering. Abstract Despite momentous divergence from oceanic origin, human beings and marine organisms exhibit elemental homology through silicon utilization. Notably, silicon serves as a critical constituent in multiple biomedical processes.
Yahui Han, Zhibo Yang, Wei Xia, Chengtie Wu   +3 more
wiley   +1 more source

Advanced 3D cancer models for analyzing tumor-immune cell interaction and therapeutic response. [PDF]

Mol Cancer
Jeevanandan SP, Reidy E, Clegg J, Curvello R, Ryan AE, Loessner D.   +5 more
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source

B Cell Subsets and Atherosclerosis: Updates and Emerging Concepts. [PDF]

Immunol Rev
Lems S, Mazzei MG, Foks AC, McNamara CA.
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. [PDF]

Theranostics
Kim RK, Heo CK, Choi MJ, Kahm YJ, Kim MK, Lee M, Lee JY, Park H, Jung U, Shin BC, Kim BJ, Kim SC, Cho EW, Ryu CJ, Kim IG.   +14 more
europepmc   +1 more source

Glycosylated dendrimer nanoamplifiers hijack DNA damage‐immune crosstalk for enhanced dual‐track therapy of orthotopic glioblastoma

BMEMat, EarlyView.
A glycosylated dendrimer nanoamplifier hijacks DNA damage‐immune crosstalk for enhanced radio‐immunotherapy of glioblastoma. The responsive release of demethylcantharidin simultaneously blocks repair‐mediated resistance by inhibiting DNA repair and overcomes adaptive immune resistance.
Cong Song, Binghan Liu, Junjie Liu, Ce Li, Wenqing Man, Xurui Sun, Chang Yuan, Yanjun Wang, Hong Pan, Shuanglian Wang, Zhiming Zheng   +10 more
wiley   +1 more source

Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer. [PDF]

Curr Treat Options Oncol
Weiner-Gorzel K, McSorley L, Walshe JM.
europepmc   +1 more source